Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down22.050 -0.300 (-1.342%)
Research Report

24/09/2020 18:01

{I-bank focus}UBS starts Alibaba Health (00241) at HK$26

[ET Net News Agency, 24 September 2020] UBS Global Research initiated coverage on
Alibaba Health Information Technology (00241) with a "buy" rating and a target price of
The research house likes Ali Health for its potential to reshape the traditional
pharmaceutical distribution model. It added that Ali Health could leverage off large
e-commerce customers and merchants on the Taobao and Tmall platforms, and also other user
flow on DingTalk and other OTO platforms such as Koubei.
UBS said current stock price mainly reflects the effect of COVID-19, but not fully the
sector's long-growth potential; UBS forecast a 40% revenue CAGR over 2019-25 for sector
leaders. (KL)

Remark: Real time quote last updated: 12/04/2021 12:36
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.